ELAN vs. RPRX: Elanco Animal Health vs. Royalty Pharma Stock Comparison
How do Elanco Animal Health (ELAN) and Royalty Pharma (RPRX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Elanco Animal Health (ELAN) and Royalty Pharma (RPRX) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
| Profile Item | ELAN | RPRX |
|---|---|---|
| Name | Elanco Animal Health Incorporated | Royalty Pharma plc Class A Ordinary Shares |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 12.86 billion USD | 38.70 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | September 20, 2018 | June 16, 2020 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ELAN | RPRX |
|---|---|---|
| Total Return (1Y) | 24.03% | 81.08% |
| Total Return (3Y, Annualized) | 37.47% | 39.21% |
| Total Return (5Y, Annualized) | -4.24% | 14.22% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Elanco Animal Health (ELAN) has an aggressive beta of 1.65, indicating higher sensitivity to broad-market moves, while Royalty Pharma (RPRX) is defensive at 0.36 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.
| Metric | ELAN | RPRX |
|---|---|---|
| Volatility (1Y, Annualized) | 43.57% | 22.05% |
| Beta (5Y) | 1.65 | 0.36 |
| Max Drawdown (5Y) | -75.59% | -41.98% |
| Avg. Volume (3M) | 5.65M | 3.10M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ELAN | RPRX |
|---|---|---|
| Sharpe Ratio (1Y) | 0.45 | 3.48 |
| Sortino Ratio (1Y) | 0.66 | 5.72 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Royalty Pharma (RPRX) earns 12.09% on shareholders’ equity, ranked against its industry; Elanco Animal Health (ELAN) has no ROE this period.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ELAN
- --
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.09%
- Max
- 109.18%
- RPRX
- 12.09%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Elanco Animal Health (ELAN) reports a negative net margin of -2.86%, usually indicating a net loss over the period. Meanwhile Royalty Pharma (RPRX) reports 25.70%, ranking against industry peers normally.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-2.86%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- ELAN
- -2.86%
- Q1
- -4.14%
- Min
- -17.05%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.70%
- RPRX
- 25.70%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Royalty Pharma (RPRX) at 81.32% operates in the top operating margin quartile, ahead of Elanco Animal Health (ELAN) at 6.64%, which runs around its industry’s norm.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64%
- Max
- 83.12%
- Q3
- 14.77%
- ELAN
- 6.64%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
81.32%
- Max
- 83.12%
- RPRX
- 81.32%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ELAN | RPRX |
|---|---|---|
| ROE (TTM) | -- | 12.09% |
| ROA (TTM) | -- | 5.43% |
| Net Margin (TTM) | -2.86% | 25.70% |
| Operating Margin (TTM) | 6.64% | 81.32% |
| Gross Margin (TTM) | 56.18% | 99.79% |
Growth
Revenue Growth
Both Elanco Animal Health (ELAN) at 6.22% and Royalty Pharma (RPRX) at 5.06% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Royalty Pharma (RPRX) at 23.09% is around its peer norm for EPS growth, while Elanco Animal Health (ELAN) at -169.12% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | ELAN | RPRX |
|---|---|---|
| Revenue Growth (YoY) | 6.22% | 5.06% |
| Revenue Growth (3Y CAGR) | 2.25% | 2.06% |
| EPS Growth (YoY) | -169.12% | 23.09% |
| EPS Growth (3Y CAGR) | -- | 161.10% |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Royalty Pharma (RPRX) shows current ratio of 1.29 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ELAN
- --
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.29
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- RPRX
- 1.29
- Min
- 0.10
Debt / Equity (MRQ)
Elanco Animal Health (ELAN) at 0.64 carries an industry-typical debt-to-equity mix, while Royalty Pharma (RPRX) at 0.88 uses more debt funding than most peers.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.64
- Max
- 1.42
- Q3
- 0.65
- ELAN
- 0.64
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.88
- Max
- 1.42
- RPRX
- 0.88
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ELAN | RPRX |
|---|---|---|
| Current Ratio (MRQ) | -- | 1.29 |
| Debt / Equity (MRQ) | 0.64 | 0.88 |
| Net Debt / EBITDA | 3.49 | 4.76 |
Dividends
Dividend Yield (TTM)
Elanco Animal Health (ELAN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a yield of 1.37%, ranking against industry peers normally.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.37%
- RPRX
- 1.37%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Elanco Animal Health (ELAN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a payout of 60.46%, ranking against industry peers normally.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
60.46%
- RPRX
- 60.46%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ELAN | RPRX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.37% |
| Dividend Payout Ratio (TTM) | 0.00% | 60.46% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Royalty Pharma (RPRX) trades at 43.99 times trailing earnings, ranked against its peers, while Elanco Animal Health (ELAN) has no P/E ratio this period.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ELAN
- --
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.99
- Max
- 85.34
- RPRX
- 43.99
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Elanco Animal Health (ELAN) at 2.50 sits in the cheaper P/S ratio quartile while Royalty Pharma (RPRX) at 14.79 prices around its industry’s middle — ELAN costs less per dollar of sales, though read it alongside growth and margins.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ELAN
- 2.50
- Min
- 0.01
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.79
- Max
- 58.18
- Q3
- 25.77
- RPRX
- 14.79
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Elanco Animal Health (ELAN) at 1.95 and Royalty Pharma (RPRX) at 4.39 are valued close to their industries’ norm against book — neither stands out from peers.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.95
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- ELAN
- 1.95
- Q1
- 1.69
- Min
- -5.59
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.39
- Max
- 13.53
- Q3
- 6.54
- RPRX
- 4.39
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ELAN | RPRX |
|---|---|---|
| P/E Ratio (TTM) | -- | 43.99 |
| P/S Ratio (TTM) | 2.50 | 14.79 |
| P/B Ratio (MRQ) | 1.95 | 4.39 |
| Free Cash Flow Yield (TTM) | -- | -1.16% |